IPO - Profile


We are a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. An irreversible small molecule drug is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in irreversible binding chemistry and development, we built our proprietary FUSION System discovery platform to More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 9,000,000 Positive High 39.89%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 15 Apr, 2021

Offer 16 Apr, 2021

Look Ahead

Lock Up Expiry Oct 16, 2021

IPO Terms

Offer Price $17.00
Offer Size 9M

Market Sentiments

Stock Price